Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2006 pubmed 268 citations

An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7.

Nagaoka. Isao I; Tamura. Hiroshi H; Hirata. Michimasa M

Key Findings

  • LL‑37 reduces neutrophil apoptosis in a dose‑dependent manner (0.01‑5 µg/ml)
  • The anti‑apoptotic effect involves ERK‑1/2 activation, increased Bcl‑xL, and reduced caspase‑3 activity
  • Blocking FPRL1 or P2X7 receptors lessens LL‑37’s ability to prevent neutrophil death, while activating these receptors mimics the effect

Practical Outcomes

  • While the findings highlight a potential way to boost innate immunity by prolonging neutrophil lifespan, LL‑37 isn’t currently available as a safe, oral supplement, and the study used isolated cells in a lab. For biohackers, the takeaway is that targeting the FPRL1 or P2X7 pathways might be a future strategy, but more research is needed before any real‑world protocol can be recommended.

Summary

The study shows that the natural peptide LL‑37, which our bodies make to fight infections, can also keep immune cells called neutrophils alive longer by stopping their programmed death, and it does this through two specific cell receptors.

Abstract

Peptide antibiotics possess the potent antimicrobial activities against invading microorganisms and contribute to the innate host defense. An antibacterial cathelicidin, human cationic antibacterial protein of 18 kDa/LL-37, not only exhibits potent bactericidal activities against Gram-negative and Gram-positive bacteria, but also functions as a chemoattractant for immune cells, including neutrophils. During bacterial infections, the life span of neutrophils is regulated by various pathogen- and host-derived substances. In this study, to further evaluate the role of LL-37 in innate immunity, we investigated the action of LL-37 on neutrophil apoptosis. Neutrophil apoptosis was assessed using human blood neutrophils based on the morphological changes. Of note, LL-37 dose dependently (0.01-5 microg/ml) suppressed neutrophil apoptosis, accompanied with the phosphorylation of ERK-1/2, expression of Bcl-x(L) (an antiapoptotic protein), and inhibition of caspase 3 activity. Interestingly, LL-37-induced suppression of neutrophil apoptosis was attenuated by the antagonists for formyl-peptide receptor-like 1 (FPRL1) and P2X7 nucleotide receptor. Of importance, the agonists for FPRL1 and P2X7 apparently suppressed neutrophil apoptosis. Collectively, these observations indicate that LL-37 cannot only kill bacteria, but also modulate (suppress) neutrophil apoptosis via the activation of FPRL1 and P2X7 in bacterial infections. Suppression of neutrophil apoptosis results in the prolongation of their life span, and may be advantageous for host defense against bacterial invasion.

Study Information

Provider

pubmed

Year

2006

Date

2006-03-01T00:00:00.000Z

DOI

10.4049/jimmunol.176.5.3044

Citations

268

References

68